Page 1

NovaBridge NovaBridge Reports First Half 2026 Financial Results and Highlights Pipeline Momentum and Strategic Execution August 20 , 2026 • Executing NovaBridge's strategy to identify differentiated science , develop it efficiently and create long - term value for patients and shareholders • Appointed Srishti Gupta , MD , MPP , as Chief Executive Officer , to strengthen strategic oversight , governance , and capital allocation across the Company • Advancing givastomig toward initiating a registrational Phase 3 study as early as YE 2026 , under a potential Accelerated Approval Pathway • Progressing VIS - 101 toward Phase 2b initiation in 2H 2026 , following positive Phase 2a results supporting potential best - in - class durability • Maintained a strong balance sheet with $ 215.9 million in cash , cash equivalents , short - term investments , and equity investment at fair value as of June 30 , 2026 , providing runway through several important clinical and strategic inflection points , including givastomig's planned Phase 3 interim data read - out in 2028 ROCKVILLE , Md . , Aug. 20 , 2026 ( GLOBE NEWSWIRE ) NovaBridge Biosciences ( Nasdaq : NBP ) ( " NovaBridge " or the " Company " ) , a global biotechnology company that identifies differentiated innovation and applies disciplined development , financing , and partnering strategies to create value , today reported financial results for the six months ended June 30 , 2026 , and provided a business update . During the first half of 2026 , the Company continued executing its strategic priorities by progressing key clinical milestones for its lead programs . The Company also strengthened leadership , governance , and capital allocation to support long - term value creation . " Significant innovation exists across geographies and organizations , yet many promising therapies never reach their full potential , " said Srishti Gupta , MD , MPP , Chief Executive Officer of NovaBridge . " NovaBridge was built to identify those opportunities , advance them efficiently and create value through the path best suited to each asset . The progress of givastomig and VIS - 101 reflects our ability to both identify differentiated science and to achieve meaningful development milestones , positioning NovaBridge to continue creating value for patients and shareholders . " " NovaBridge is building the capabilities required to succeed over the long term . The progress of givastomig and VIS - 101 , together with the continued strengthening of the organization , reflects deliberate execution against that objective , " said Fu Wei , Chairman of the Board of NovaBridge . Pipeline Overview and Potential Upcoming Milestones NovaBridge's two lead programs illustrate the complementary capabilities at the core of its strategy . Givastomig , a potential first- in - class Claudin 18.2 - Targeted Immuno Amplifier ( " CTIA " ) , reflects NovaBridge's ability to efficiently execute differentiated science toward registrational development . VIS - 101 , a purpose - designed tetravalent VEGF - A × ANG - 2 peptibody for retinal vascular diseases , developed through NovaBridge's majority - owned subsidiary leading its ophthalmology platform , Visara , Inc. ( " Visara " ) , reflects NovaBridge's ability to identify and acquire differentiated therapeutic assets that others have overlooked . Givastomig Givastomig is a potential first - in - class CTIA . It is a bispecific Claudin 18.2 × 4-1BB antibody targeting Claudin 18.2 - positive tumor cells being developed for the treatment of first - line metastatic gastric cancer . In January 2026 , NovaBridge reported positive data from the givastomig Phase 1b dose expansion combination study in patients with first - line ( " 1L " ) gastric cancer . The data showed that givastomig produced a 77 % ORR at 8 mg / kg and 73 % ORR at 12 mg / kg ( among 52 evaluable subjects ) , and a 16.9 - month median progression - free survival at 8 mg / kg ( among 27 evaluable subjects ) , with responses observed across a range of PD - L1 and Claudin 18.2 expression levels . Givastomig demonstrated favorable overall tolerability in combination with immunochemotherapy without dose - dependent toxicity . In February 2026 , NovaBridge initiated a global , randomized Phase 2 study of givastomig combined with immunochemotherapy in patients with HER2 - negative , 1L metastatic gastric cancer .